Imalumab

Drug Profile

Imalumab

Alternative Names: Anti-macrophage migration inhibitory factor antibody - Shire; Anti-MIF monoclonal antibody - Shire; BAX-069; BAX-69

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytokine PharmaSciences
  • Developer Baxalta; Shire
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Macrophage migration inhibitory factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Malignant ascites
  • No development reported Solid tumours
  • Discontinued Lupus nephritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Germany (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in USA (IV, Injection)
  • 02 Jun 2017 Baxalta terminates a phase II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Spain (NCT02448810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top